|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||50.44 - 51.57|
|52-week range||48.01 - 166.10|
|Beta (5Y monthly)||0.33|
|PE ratio (TTM)||N/A|
|Earnings date||05 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||115.91|
Shares of Galapagos (NASDAQ: GLPG), a biopharmaceutical company, are under pressure following clinical trial readouts for a couple of new drug candidates in phase 1 studies. Disappointing results from the company's Toledo program pushed the stock 13.1% lower as of 3:52 p.m. EDT on Thursday. Following the implosion of Jyseleca in the U.S., Galapagos has leaned on its early clinical-stage pipeline to get attention from investors.
Galapagos (GLPG) announces data from multiple studies evaluating its two inflammatory candidates - GLPG3970 and GLPG3667. Stock down.
Generally safe and well toleratedPositive efficacy signal in psoriasis patients at Week 440% of patients showed improvement of at least 50% in PASI response (PASI 50) with high dose of GLPG3667 at Week 4Data support initiation of Phase 2b dose finding study in psoriasis Mechelen, Belgium; 14 July 2021; 22.01 CET; regulated information - Galapagos NV (Euronext & Nasdaq: GLPG) reports positive topline results with tyrosine kinase 2 (TYK2) inhibitor GLPG3667 in a Phase 1b study in psoriasis patient